Skip to main content

Venture Life Group plc (AIM:VLG)

London flag London · Delayed Price · Currency is GBP · Price in GBX
58.60
-2.90 (-4.72%)
Apr 28, 2026, 4:35 PM GMT
44.69%
Market Cap 71.39M
Revenue (ttm) 35.17M
Net Income (ttm) 6.13M
Shares Out 121.83M
EPS (ttm) 0.05
PE Ratio 11.66
Forward PE 14.29
Dividend n/a
Ex-Dividend Date n/a
Volume 232,041
Average Volume 128,080
Open 61.00
Previous Close 61.50
Day's Range 58.00 - 62.00
52-Week Range 40.00 - 72.00
Beta 0.32
RSI 23.82
Earnings Date May 13, 2026

About Venture Life Group

Venture Life Group plc develops and commercializes healthcare products in the United Kingdom. The company offers oral healthcare products, including mouthwash, toothpaste, breath freshening capsules, and dental accessories under UltraDEX and Dentyl Dual Action brands; and proctology products, such as Procto-eze Plus range for treating the discomfort caused by haemorrhoids. It also provides dermatology products comprising Myco Clear, a fungal nail cleanser and solution brand; Rosa calma for normalizing and controlling the signs and symptoms rela... [Read more]

Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Founded 2005
Employees 43
Stock Exchange London Stock Exchange AIM
Ticker Symbol VLG
Full Company Profile

Financial Performance

Financial Statements

News

Venture Life Group Earnings Call Transcript: H2 2025

Major divestments and a shift to a brand-focused model drove 11% organic and 32% reported revenue growth, with strong cash generation and double-digit growth continuing into 2026. Power brands excelled, especially in women's and men's health, while digital transformation and innovation underpin future expansion.

26 days ago - Transcripts

Venture Life Group Earnings Call Transcript: H1 2025

Revenue grew 43% to £15.4m, with 12.5% organic growth and gross margin up to 43.1%. Strong cash position and divestment of non-core assets support a brand-focused, high-margin strategy, with continued investment in innovation, marketing, and M&A.

7 months ago - Transcripts

Venture Life Group Earnings Call Transcript: H2 2024

Year-end 2024 results show a strategic pivot to a capital-light, high-margin brand model, with strong growth in core segments and the Health & Her acquisition accelerating U.K. and U.S. expansion. Divestments provide cash for organic growth and M&A, with further margin gains expected.

10 months ago - Transcripts

Venture Life Group Transcript: Investor Update

Divestment of CDMO operations and peripheral brands streamlines the business into a focused, high-margin consumer healthcare platform. Proceeds will fund core brand growth, innovation, and M&A, with enhanced digital capabilities and expansion in key markets.

1 year ago - Transcripts

Venture Life Group Earnings Call Transcript: H2 2023

2 years ago - Transcripts

Venture Life Group Transcript: Status Update

2 years ago - Transcripts

Venture Life Group Transcript: Status Update

2 years ago - Transcripts

Venture Life Group Earnings Call Transcript: H1 2023

2 years ago - Transcripts

Venture Life Group Transcript: Status Update

2 years ago - Transcripts

Venture Life Group Transcript: CMD 2023

3 years ago - Transcripts